Mineralys Therapeutics appointed Kristine Peterson and Lonnel Coats to its Board of Directors to strengthen leadership as it approaches the FDA decision on lorundrostat, a drug for resistant hypertension, scheduled for December 22, 2026. Both new directors bring extensive commercial and product launch experience in cardiovascular and metabolic diseases, supporting Mineralys' transition to a commercial-stage company. This move aims to enhance the company's readiness for the potential approval and market launch of lorundrostat, which targets hypertension driven by aldosterone dysregulation. The appointments reflect Mineralys' strategic focus on expanding its leadership to boost commercial success and operational execution.
Mineralys Therapeutics' board expansion provides context for readers interested in health-sector developments. For readers following health-sector stocks on Pluang, here is the market snapshot as of Oct 20, 2026 03:02 WIB: out of 150 priced US health stocks, 87 rose and 62 fell. Relay Therapeutics Inc. (RLAY) gained 4.79% to USD 17.06 with a typical hold time of 10 days, while Recursion Pharmaceuticals Inc. (RXRX) rose 4.76% to USD 3.63 despite a Pluang order activity skewed 72% sell. DENTSPLY SIRONA Inc. (XRAY) increased 4.74% to USD 8.84 with a notably longer typical hold time of 73 days.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
